<u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

<u>Materials</u>

Antibodies	Yes (indicate where provided:	n/a
For commercial reagents, provide supplier		No commercial
name, catalogue number and RRID, if		reagents
Cell materials	Yes (indicate where provided:	n/a
Cell lines: Provide species information,		No cell line
strain. Provide accession number in		
repository OR supplier name, catalog		
number, clone number, OR RRID		
Primary cultures: Provide species, strain,		No relative species
sex of origin, genetic modification status.		
Experimental animals	Yes (indicate where provided:	n/a
Laboratory animals: Provide species, strain,		No animals
sex, age, genetic modification status. Provide		
accession number in repository OR supplier		
name, catalog number, clone number, OR RRID		
Animal observed in or captured from the		No laboratory animals
field: Provide species, sex and age where		
possible		
Model organisms: Provide Accession		No animals
number in repository (where relevant) OR		
Plants and microbes	Voc (indicate where provided:	n/a
	Yes (indicate where provided:	10.00
Plants: provide species and strain, unique		No plants
accession number if available, and source		
(including location for collected wild specimens)		
Microbes: provide species and strain,		No microbes
unique accession number if available, and		
Human research participants	Yes (indicate where provided:	n/a
Identify authority granting ethics approval (IRB		🐱
or equivalent committee(s), provide reference	Materials and methods/ para	
number for approval.	1	
Provide statement confirming informed consent	1	N/A
obtained from study participants.		14//
Report on age and sex for all study participants.		N/A
ricport on age and sex for all study participants.		1 1// 1

<u>Design</u>

	V (' 1' 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	,
Study protocol	Yes (indicate where provided:	n/a
For clinical trials, provide the trial registration		No clinical trials
number OR cite DOI in manuscript.		
	1	
Laboratory protocol	Yes (indicate where provided:	n/a
Provide DOI or other citation details if detailed		No relative
step-by-step protocols are available.		protocol
Experimental study design (statistics details)	Yes (indicate where provided:	n/a
State whether and how the following have been	. 35 (maiotic where provided.	11/ 4
done, or if they were not carried out.		
Sample size determination		N/A
Randomisation		N/A
Blinding		No blinding
Inclusion/exclusion criteria		All be included
Sample definition and in-laboratory	Yes (indicate where provided:	n/a
State number of times the experiment was		N/A
replicated in laboratory		
Define whether data describe technical or		N/A
biological replicates		
Ethics	Yes (indicate where provided:	n/a
Studies involving human participants: State	Materials and methods/ para 1	11/ d
	Materials and methods/ para 1	
TOBIAIS OF AUTHORITY DESCRIPTION BEHING SUPPOVALUER	I .	
details of authority granting ethics approval (IRB or equivalent committee(s), provide reference		
or equivalent committee(s), provide reference		
or equivalent committee(s), provide reference number for approval.		N/A
or equivalent committee(s), provide reference number for approval. Studies involving experimental animals: State		N/A
or equivalent committee(s), provide reference number for approval. Studies involving experimental animals: State details of authority granting ethics approval (IRB		N/A
or equivalent committee(s), provide reference number for approval. Studies involving experimental animals: State		N/A
or equivalent committee(s), provide reference number for approval. Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		N/A
or equivalent committee(s), provide reference number for approval. Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference		
or equivalent committee(s), provide reference number for approval. Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval. Studies involving specimen and field samples:		
or equivalent committee(s), provide reference number for approval. Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval. Studies involving specimen and field samples: State if relevant permits obtained, provide		
or equivalent committee(s), provide reference number for approval. Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval. Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.		N/A
or equivalent committee(s), provide reference number for approval. Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval. Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why. Dual Use Research of Concern (DURC)	Yes (indicate where provided:	N/A n/a
or equivalent committee(s), provide reference number for approval. Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval. Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why. Dual Use Research of Concern (DURC) If study is subject to dual use research of	Yes (indicate where provided:	N/A
or equivalent committee(s), provide reference number for approval. Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval. Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why. Dual Use Research of Concern (DURC)	Yes (indicate where provided:	N/A n/a

<u>Analysis</u>

Attrition	Yes (indicate where provided:	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.		N/A
were determined and specified in advance.		
Statistics	Yes (indicate where provided:	n/a
Describe statistical tests used and justify choice of tests.	Materials and methods/ para 6	
Data Availability	Yes (indicate where provided:	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.		N/A
If data are publicly available, provide accession number in repository or DOI or URL.		N/A
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.		N/A

Code Availability	Yes (indicate where provided:	n/a
For all newly generated code and software		N/A
essential for replicating the main findings of the		
State whether the code or software is available.		N/A
If code is publicly available, provide accession number in repository, or DOI or URL.		N/A

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.	economy panagraphy	N/A
State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.		N/A

Article information: https://dx.doi.org/10.21037/tro-21-43